Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0312414 (Spotting)
 88 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The Fertility Control Clinic, National University Hospital in Singapore carried out this study between Jan.1988-Dec.1988. In a comparison of present and past users of contraceptive implants (Norplant) or injectables (DMPA) and discontinuers of Norplant or DMPA, information concerning the women's knowledge and perception of, and attitude to, implants and injectable contraceptives, was studied. 200 married women ages 20-45 with at least 1 living child, who had used either method for at least 1 year, took part in this survey. The long duration of action (5 years) of implants was perceived positively by all groups as compared to the shorter 3-month duration of injectables, though this was seen as an advantage over the pill. 69% of implant users expressed a desire to continue using them, but only 30.7% of the injectable users wanted to continue using the method. 60% of the injectable users wanted to switch to implants, whereas no implant users desired a change. Women stopped using these 2 methods mainly because of the desire for a future pregnancy, menstrual spotting, and absence of menses. Norplant seems to be the ideal contraceptive in Singapore for women who do not want any more children or irreversible contraception.
 ...
PMID:Attitudes towards contraceptive implants and injectables among present and former users in Singapore. 210 23

Use of Depo-Provera for contraception during the postpartum period is reported. Contraceptive efficiency of 100% for more than 6 months was observed after injections of 150 mg on the 5th day postpartum and after 3 months. Estragenital and lactation side effects were negligeable. Spotting was observed in 21 patients, and bleeding in 7. Physiological amenorrhea continued to the 7th month in 24 patients. The authors believe that depoprovera is particularly indicated, and has fewer side effects, in the puerperium.
 ...
PMID:[Use of Depo Provera as a contraceptive in the puerperium]. 473 12

35 predominantly multiparous, sexually active women aged 25-44 years were fitted with levonorgestrel 20 T (Schering) IUDS in the post- menstrual phase, or in rare instances, right after abortion. the devices contained 60 mg of levonorgestrel releasing 20 mcg/day with the life span of 5 years. The patients were followed up every 3-6 months to detect side effects and complications. The first year contained a total of 339 months of observation, while the figure rose to 461 months in the second year. Spotting lasting 15-20 days followed insertion, but in later months only 7% of patients complained of bleeding or menstrual spotting. 7-8% of cases tended to have oligomenorrhea in the first year; 1/3 to 1/2 of them had hypomenorrhea during the first and second year. True amenorrhea started in 20-30% of women, persisting through both years. Longer duration of flow occurred in 32.4-4.57.1% of cases during these 2 years. Hormonal effects (headache, acne, hirsutism, depression, mastalgia, and inflamed varicose veins) ranged from 18.2- 33.3%. Levonorgestrel 20 T demonstrated more superior contraceptive efficacy than Progestasert; however, serious menstrual cycle disorders associated with it also increased. All progestin-releasing devices (the minipill, Norplant, Progestasert) induced menstrual changes, thus their use is preferable for therapeutic indications such as hypermenorrhea and uterine fibroid.
 ...
PMID:[Two-year clinical performance of the Levonorgestrel 20 T IUD]. 1231 72